Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

SIMPLE SUMMARY: By coupling the potency of cytotoxic chemotherapy with the selectivity of targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of antitumor agents. In this review, we aim to outline the unanswered questions that have emerged after the approval of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vathiotis, Ioannis A., Bafaloukos, Dimitrios, Syrigos, Konstantinos N., Samonis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954068/
https://www.ncbi.nlm.nih.gov/pubmed/36831628
http://dx.doi.org/10.3390/cancers15041286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954068/
https://www.ncbi.nlm.nih.gov/pubmed/36831628
http://dx.doi.org/10.3390/cancers15041286

Ejemplares similares